<div id="readability-page-1"><p><span>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report)</span> was downgraded by stock analysts at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Saturday.</p><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>A number of other equities analysts also recently issued reports on TEVA. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a &#34;sector outperform&#34; rating and a $35.00 price objective on the stock. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 24th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued  a Buy rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat, the company  has an average rating of &#34;Buy&#34; and a consensus price target of $30.25.</p><p><b>Check Out Our Latest Stock Analysis on TEVA</b></p><h2>Teva Pharmaceutical Industries Trading Down 1.3%</h2><ul><li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li></ul><p>Teva Pharmaceutical Industries stock opened at $29.80 on Friday. The business has a 50-day simple moving average of $23.43 and a two-hundred day simple moving average of $19.60. The company has a market cap of $34.18 billion, a P/E ratio of 49.67, a P/E/G ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $30.20. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. </p><h2>Insider Activity at Teva Pharmaceutical Industries</h2><p>In related news, Director Roberto Mignone sold 200,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company's stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the company's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company's stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by company insiders. </p><h2>Hedge Funds Weigh In On Teva Pharmaceutical Industries</h2><ul><li>2 Generic Drug Stocks Ready to Surge in 2025</li></ul><p>Institutional investors have recently bought and sold shares of the stock. Cromwell Holdings LLC lifted its position in shares of  Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock worth $44,000 after buying an additional 629 shares in the last quarter.  Advisors Asset Management Inc. purchased a new stake in shares of  Teva Pharmaceutical Industries during the 2nd quarter worth approximately $41,000.  Rothschild Investment LLC boosted its position in shares of  Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock valued at $55,000 after acquiring an additional 1,348 shares during the last quarter.  JFS Wealth Advisors LLC boosted its position in shares of  Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock valued at $56,000 after acquiring an additional 2,000 shares during the last quarter.  Finally, LRI Investments LLC grew its holdings in shares of  Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company's stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors. </p><h2>Teva Pharmaceutical Industries Company Profile</h2> (Get Free Report)<p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p><h2>See Also</h2><ul><li>Five stocks we like better than Teva Pharmaceutical Industries</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>Insider Buying Explained: What Investors Need to Know</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>Investing In Preferred Stock vs. Common Stock</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TEVA

<p>Wall Street Zen lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Saturday.</p>

Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by Wall Street Zen to Buy